13,282 Shares in Sera Prognostics, Inc. (NASDAQ:SERA) Bought by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC bought a new position in Sera Prognostics, Inc. (NASDAQ:SERA) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 13,282 shares of the company’s stock, valued at approximately $104,000.

A number of other hedge funds have also modified their holdings of the stock. SG Americas Securities LLC acquired a new position in shares of Sera Prognostics in the 3rd quarter worth $78,000. The Manufacturers Life Insurance Company purchased a new position in shares of Sera Prognostics during the second quarter valued at $68,000. Renaissance Technologies LLC purchased a new position in shares of Sera Prognostics during the second quarter valued at $162,000. American Century Companies Inc. grew its holdings in shares of Sera Prognostics by 12.7% during the second quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock valued at $152,000 after buying an additional 2,891 shares in the last quarter. Finally, Ballentine Partners LLC purchased a new position in shares of Sera Prognostics during the second quarter valued at $294,000. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Zhenya Lindgardt sold 25,085 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $7.57, for a total value of $189,893.45. Following the sale, the chief executive officer now directly owns 831,833 shares in the company, valued at approximately $6,296,975.81. This represents a 2.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Austin Aerts sold 5,056 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $7.57, for a total value of $38,273.92. Following the completion of the sale, the chief financial officer now owns 298,665 shares in the company, valued at approximately $2,260,894.05. This represents a 1.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 58,487 shares of company stock valued at $435,628 over the last quarter. Insiders own 15.80% of the company’s stock.

Sera Prognostics Trading Down 4.7 %

Shares of SERA stock opened at $6.14 on Monday. The company has a market capitalization of $204.89 million, a price-to-earnings ratio of -6.20 and a beta of 1.04. Sera Prognostics, Inc. has a 1-year low of $1.72 and a 1-year high of $12.35. The stock’s fifty day simple moving average is $7.36 and its 200-day simple moving average is $7.55.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.09 million. During the same period in the prior year, the company earned ($0.23) earnings per share. On average, sell-side analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.